Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic

Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic

Submitted by admin on July 14, 2021 - 10:35am
Source: 
Fierce Biotech
News Tags: 
Ribon Therapeutics
funding
PARP7 inhibitors
Headline: 
Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic
snippet: 

Ribon Therapeutics has raised $65 million to advance a  pipeline led by a PARP7 inhibitor deeper into the clinic. The financing positions Ribon to build on work to target stress support pathways in cancer and inflammation.

Do Not Allow Advertisers to Use My Personal information